文献速递乳腺MR

乳腺癌新辅助化疗后增强MRI:病灶与背景实质信号增强比对区分病理完全缓解与微小残留肿瘤

Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
PubMed 文献 · Eur Radiol · 2018-01-29

本研究回顾性纳入216例新辅助化疗后经手术病理证实为病理完全缓解或微小残留癌的乳腺癌患者,分析MRI早期相病灶与背景实质信号增强比(SER)。SER与病理完全缓解独立相关,SER≤1.6较常规标准提高了AUC和特异度;SER≤1.6和/或病灶≤0.2cm标准特异度最高达90.4%。

要点

  • 早期相SER≤1.6较常规标准提高识别病理完全缓解的AUC和特异度。
  • SER≤1.6和/或病灶≤0.2cm标准特异度最高,为90.4%。
  • 单纯测量信号强度即可区分病理完全缓解与微小残留癌。

核心结论

  • 早期相MRI的SER与病理完全缓解独立相关,较常规标准提高了AUC和特异度;SER联合病灶大小的标准可用于未来研究中筛选避免手术的候选者。

研究设计与样本

  • 回顾性研究,纳入216例接受新辅助化疗且MRI后手术病理证实为病理完全缓解或微小残留癌的乳腺癌患者,分析临床病理特征、SER及MR图像上的病灶大小,采用多因素logistic回归、ROC曲线和McNemar检验。

诊断标准与关键数值

  • 早期相MRI的SER与病理完全缓解独立相关:读者1 OR 0.286(95%CI 0.113-0.725),p=.008;读者2 OR 0.306(95%CI 0.111-0.841),p=.022。
  • SER≤1.6标准较常规标准提高AUC(0.709-0.771 vs. 0.585-0.599,p=.001-.033)和特异度(80.8-86.3% vs. 21.9-27.4%,p<.001)。
  • SER≤1.6和/或病灶≤0.2cm标准特异度最高,为90.4%。

临床应用与阅片要点

  • 作者认为SER联合病灶大小的标准可用于未来研究中筛选避免手术的候选者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To retrospectively investigate whether the lesion-to-background parenchymal signal enhancement ratio (SER) on breast MRI can distinguish pathological complete response (pCR) from minimal residual cancer following neoadjuvant chemotherapy (NAT), and compare its performance with the conventional criterion.

METHODS: 216 breast cancer patients who had undergone NAT and MRI and achieved pCR or minimal residual cancer on surgical histopathology were included. Clinical-pathological features, SER and lesion size on MR images were analysed. Multivariate logistic regression, ROC curve and McNemar's test were performed.

RESULTS: SER on early-phase MR images was independently associated with pCR (odds ratio [OR], 0.286 [95% CI: 0.113-0.725], p = .008 for Reader 1; OR, 0.306 [95% CI: 0.111-0.841], p = .022 for Reader 2). Compared with the conventional criterion, SER ≤1.6 increased AUC (0.585-0.599 vs. 0.709-0.771, p=.001-.033) and specificity (21.9-27.4% vs. 80.8-86.3%, p <.001) in identifying pCR. SER ≤1.6 and/or size ≤0.2 cm criterion showed the highest specificity of 90.4%.

CONCLUSION: SER on early-phase MR images was independently associated with pCR, and showed improved AUC and specificity compared to the conventional criterion. The combined criterion of SER and size could be used to select candidates to avoid surgery in a future study.

KEY POINTS: • Compared with conventional criterion, SER ≤ 1.6 criterion increased AUC and specificity. • Simple measurement of signal intensity could differentiate pCR from minimal residual cancer. • SER ≤1.6 and/or size≤0.2cm criterion showed the highest specificity of 90.4 %. • The combined criterion could be used for a study to avoid surgery.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim SY, Cho N, Shin SU, et al. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour. Eur Radiol. 2018. PMID: 29380033. doi:10.1007/s00330-017-5251-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。